Should You Buy Hikma Pharmaceuticals Plc, Circassia Pharmaceuticals PLC & Hutchison China MediTech Limited On Today’s News?

Can Hikma Pharmaceuticals Plc (LON:HIK), Circassia Pharmaceuticals PLC (LON:CIR) and Hutchison China MediTech Limited (LON:HCM) boost your portfolio?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

How good is the investment case for Hikma Pharmaceuticals (LSE: HIK), Circassia Pharmaceuticals (LSE: CIR) and Hutchison China MediTech (LSE: HCM) after all three firms released news today?

Hikma Pharmaceuticals

Hikma Pharmaceuticals has grown so big since listing on the stock market in 2005 that it was promoted to the FTSE 100 earlier this year. Acquisitions have been part of Hikma’s growth strategy, but today it announced its biggest deal to date.

Hikma is to acquire Roxane Laboratories and Boehringer Ingelheim Roxane (together “Roxane”) from parent company Boehringer Ingelheim for a total consideration of $2.65bn: $1.18bn in cash and 40 million new Hikma shares at £23.50 a share.

Roxane is a US generics company, and the acquisition will catapult Hikma to the no. 6 position in the US generics market. Last year, Hikma made $763m revenue from the US and $633m from its other major territory, the Middle East and North Africa. Hikma expects Roxane to achieve revenue of $725m-$775m in 2017, and, assuming the acquisition completes in the last quarter of this year, the Board expects the deal to be accretive to adjusted earnings per share (EPS) in 2016 and “strongly accretive” to adjusted EPS from 2017 onwards.

Hikma’s shares are up over 6% in the wake of the news, but at just over £22 are below the £23.50 Boehringer Ingelheim sees as an acceptable valuation. I rate Hikma a buy at this level.

Circassia Pharmaceuticals

Circassia Pharmaceuticals is developing a pipeline of allergy treatments that are superior to traditional treatments by building up immunity quicker and without the risk of anaphylactic shocks. Circassia is in the FTSE SmallCap index, but raised £275m in June for two acquisitions and to fully fund its pipeline. As a result, the company’s market capitalisation has risen to well over £800m (at a current share price of a little under £3), putting it firmly in line for promotion to the FTSE 250 at the next quarterly review, in September.

On the face of it, this seems to be an over-elevated status for a company that is expected to be loss-making for some time to come. Circassia today reported a half-year loss widening to £22m from £16m in the same period last year, but said its “late-stage programs and phase III studies are on track” — and its share price is little changed on the day.

It’s difficult to put a valuation on Circassia, but renowned fund manager Neil Woodford was happy to participate in the June fundraising, which was at a level not much below the current share price.

Hutchison China MediTech

Hutchison China MediTech (“Chi-Med”), whose vision is to become a major China-based pharmaceutical company, reported a “strong outlook for full year and beyond” in its half-year results today. Nevertheless, the shares fell more than 7% to under £16 in early trading this morning — and well down from a high of close to £20 in May.

Chi-Med is one of the bigger companies on the AIM market, being valued at over £900m. In contrast to Circassia, the company is growing revenues fast, and is profitable. In its first-half results today, Chi-Med reported revenue on continuing operations up 117% to $65.7m. Net profit to equity holders fell to $2.3m from $5.6m, but I don’t see this as any cause for concern. Chi-Med is using cash from its profitable “Commercial Platform” of healthcare and consumer products to fund its exciting drug “Innovation Platform” — in particular, during the first half, “pushing our oncology and immunology clinical pipeline as hard and fast as we could”.

Chi-Med’s Commercial Platform already has 1,800 medical sales staff, covering about 13,500 hospitals and over 80,000 doctors — a ready-made network for commercialising the company’s own Innovation Platform drugs once approvals start to come through. With profits currently being recycled into clinical activity, valuing the company on earnings is not particularly helpful. Strong forecast revenue growth, though, and price-to-sales ratios, suggest the stock could be worth buying at the current level.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any shares mentioned. The Motley Fool UK has recommended Hikma Pharmaceuticals. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

After it crashed 25%, should I buy this former stock market darling in my Stocks and Shares ISA?

Harvey Jones has a big hole in his Stocks and Shares ISA that he is keen to fill. Should he…

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

How’s the dividend forecast looking for Legal & General shares in 2025 and beyond?

As a shareholder, I like to keep track of the potential dividend returns I could make from my Legal &…

Read more »

artificial intelligence investing algorithms
Investing Articles

Could buying this stock with a $7bn market cap be like investing in Nvidia in 2010?

Where might the next Nvidia-type stock be lurking in today's market? Our writer takes a look at one candidate with…

Read more »

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could December be a great month to buy UK shares?

Christopher Ruane sees some possible reasons to look for shares to buy in December -- but he'll be using the…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Sticking to FTSE shares, I’d still aim for a £1,000 monthly passive income like this!

By investing in blue-chip FTSE shares with proven business models, our writer hopes he can build sizeable passive income streams…

Read more »

Growth Shares

BT shares? I think there are much better UK stocks for the long term

Over the long term, many UK stocks have performed much better than BT. Here’s a look at two companies that…

Read more »

British Pennies on a Pound Note
Investing Articles

After a 540% rise, could this penny share keep going?

This penny share has seen mixed fortunes in recent years. Our writer looks ahead to some potentially exciting developments in…

Read more »